These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 16542849

  • 1. Anti-TNF therapies in the management of acute and chronic uveitis.
    Hale S, Lightman S.
    Cytokine; 2006 Feb 21; 33(4):231-7. PubMed ID: 16542849
    [Abstract] [Full Text] [Related]

  • 2. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP.
    Curr Dir Autoimmun; 2010 Feb 21; 11():180-210. PubMed ID: 20173395
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Anti-TNF-alpha treatment and spondyloarthropathies].
    Braun Y, Balbir-Gurman A.
    Harefuah; 2002 Nov 21; 141(11):965-8, 1010. PubMed ID: 12476631
    [Abstract] [Full Text] [Related]

  • 7. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A, Perez VL, Hammel JP, Lowder CY.
    Ophthalmology; 2006 Dec 21; 113(12):2317-23. PubMed ID: 16996615
    [Abstract] [Full Text] [Related]

  • 8. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice.
    Elewaut D, Matucci-Cerinic M.
    Rheumatology (Oxford); 2009 Sep 21; 48(9):1029-35. PubMed ID: 19561158
    [Abstract] [Full Text] [Related]

  • 9. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG, Markomichelakis NN, Sfikakis PP.
    Retina; 2007 Sep 21; 27(4):399-413. PubMed ID: 17420690
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Infliximab in the treatment of refractory posterior uveitis.
    Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ.
    Ophthalmology; 2003 Jul 21; 110(7):1449-53. PubMed ID: 12867408
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr 21; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 13. Favorable response to high-dose infliximab for refractory childhood uveitis.
    Kahn P, Weiss M, Imundo LF, Levy DM.
    Ophthalmology; 2006 May 21; 113(5):860-4.e2. PubMed ID: 16545455
    [Abstract] [Full Text] [Related]

  • 14. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Méndez-Fernández R, López-Abad C, Matilla M, Garcia-Sanchez J.
    Eye (Lond); 2005 Aug 21; 19(8):841-5. PubMed ID: 15389273
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.
    Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F.
    Autoimmun Rev; 2005 Mar 21; 4(3):144-52. PubMed ID: 15823500
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P, Cotena C, Tessari G, Girolomoni G.
    J Eur Acad Dermatol Venereol; 2008 Mar 21; 22(3):341-4. PubMed ID: 18005022
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.